PL-Sanok: pharmaceutical products

1. The subject-matter of the contract is the successive supply of medicinal products for the treatment of chronic SCIs: pegylated interferon and ribavirin and others for SPZOZ in Sanoku, by task,
Common Procurement Vocabulary: CPV – 33.60.00.00-6 pharmaceutical products.
A detailed description, scope and size of the subject-matter of the contract is set out in the price form set out in Annex 2 to the Specifications for Relevant Contract Terms.
The products offered must be released for free circulation in Poland. A detailed description, scope and size of the subject-matter of the contract is set out in the price form set out in Annex 2 to the Specifications for Relevant Contract Terms.
The contracting authority provides for a right of option for this contract, consisting of the possibility, during the period of performance of this contract (of 12 months from the date of signature of the contract), to purchase an increased quantity of the subject-matter of the contract in each product item by 20 % if a contract is concluded with the NFZ for the continuation of the treatments in question under the medicines programme.
2. The Contractor must offer a period of 30 days for payment of the VAT invoice from the date of its correct issue and the period during which prices remain unchanged for the duration of the contract.
The contract performance conditions are set out in the model contract, which forms an integral part of the ToR.
3. The procurer allows equivalent tenders, i.e. pharmaceutical and therapeutic equivalents.
Basic concepts and definitions relating to the bioequivalence of medicines; Kalisan and Janicki were modified.
Concept.
Definition.
Pharmaceutical equivalence.
Pharmaceutical equivalence defines a situation where the medicines being compared contain the same amount of medicinal product in the same (or essentially similar form, e.g. tablets, capsules) of the medicine, corresponding to the same comparable standards and which are intended to be administered by the same route; pharmaceutical equivalence is not a condition for therapeutic equivalence, since differences in complementary substances and in the manufacturing process may give rise to differences in dissolution and bioavailability and, consequently, in the performance of the pharmaceutical product.
Therapeutic equivalence.
Two products are therapeutically equivalent if they are pharmaceutically equivalent and if, after being administered at the same dose, their effects in terms of both efficacy and safety are those which could have been expected from appropriate studies.

33600000 - Pharmaceutical products